Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Unmet needs in the treatment and management of cold agglutinin disease

Catherine Broome • 18 Dec 2023
ASH 2023
Cold Agglutinin Disease Non-Malignant

Catherine Broome, MD, Georgetown University Hospital, Washington, DC, comments on the unmet needs in treating and managing cold agglutinin disease (CAD). Although inhibition of the classical complement pathway has addressed the hemolysis associated with the disease, targeting the complement cascade does not alter the level of autoimmune IgM antibody, which is responsible for the acrocyanosis observed in patients. Dr Broome also highlights a need to investigate and better understand the systemic impacts of this disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria: Sanofi, Alexion, Argenx, Apellis, Dianthus Therapeutics.

More from Catherine Broome

1:30
Targeting the complement cascade in autoimmune hemolytic anemias
Catherine Broome • 18 Dec 2023
1:59
Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA
Catherine Broome • 18 Dec 2023
2:50
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Catherine Broome • 18 Dec 2023
0:56
Evaluating the suitability of sHLH diagnostic criteria in adults
Catherine Broome • 12 Dec 2022

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals